Plain-English translation of NCT06486883 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether a newer medication called trastuzumab deruxtecan (T-DXd) works better than the current standard treatment—a combination of a CDK4/6 inhibitor plus hormone therapy—for people with advanced breast cancer that is hormone-sensitive but HER2-low. The goal is to see which treatment helps people live longer without their cancer getting worse.
Current standard treatments for this type of breast cancer don't work well for everyone, especially for patients whose tumors have certain genetic features. This trial is testing whether the new medication might be more effective for this specific group of patients.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will be randomly assigned to receive either the newer medication (T-DXd) given as an infusion into your vein every 3 weeks, or the current standard combination treatment of a CDK4/6 inhibitor pill plus hormone therapy. You will have regular visits to your study clinic for blood tests, scans, and check-ups to see how the treatment is working and to monitor for side effects. The study will continue until your cancer stops responding to the treatment or you experience unacceptable side effects.
AI-generated summary from trial data · Jun 30, 2026 · Not medical advice
Austria
Belgium